All In Biotech

Drug Trial Radar · NCT06858657

A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK44459 in Healthy Subjects

A Single and Multiple Ascending Dose Study to Assess the Safety,Tolerability, PK,PD and Food Effect of HSK44459 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Aug 17, 2024

Primary completion

Nov 18, 2024

Study completion Dec 20, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, randomized, subject-blinded, placebo controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD),and food effect (FE) of HSK44459 following (1) a single ascending dose (part 1), (2) 10 days of multiple ascending dose (part 2), and (3) a single dose two-period crossover FE cohort.

Conditions

  • Healthy

Interventions

  • HSK44459Drug

    Dose 1 to Dose 5

  • placeboDrug

    dose 1 to dose 5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number and severity of treatment emergent adverse events (TEAEs)Time frame: 7 days after single dose and 3 days after the first dose of multiple doses

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Drum Tower Hospital

    Nanjing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.